10. SALE OF RESEARCH AND DEVELOPMENT ASSETS (Tables)

9 Months Ended

Jan. 31, 2019

Discontinued Operations and Disposal Groups [Abstract]

Discontinued operations summary

	Three Months Ended January 31,					Nine Months Ended January 31,
	2019		2018			2019			2018
Operating expenses:
Research and development	$	–	$	374		$	–		$	7,590
Selling, general and administrative		–		1,315			–			2,097
Restructuring charges		–		–			–			330
Total operating expenses	$	–	$	1,689		$	–		$	10,017
Other expense		–		387			–			387
Gain on sale of research and development assets before income taxes	$	–		–		$	1,000			–
Income tax expense		–		–			(261	)		–
Income (loss) from discontinued operations, net of tax	$	–	$	(2,076	)	$	739		$	(10,404	)

The following table summarizes the assets and liabilities of discontinued operations as of January 31, 2019 and April 30, 2018:

	January 31, 2019		April 30, 2018
Assets:
Other receivables	$	–	$	5,000
Total assets of discontinued operations	$	–	$	5,000
Liabilities:
Accounts payable	$	–	$	32
Accrued clinical trial and related fees		–		3,613
Accrued payroll and related costs		–		614
Other liabilities		125		291
Total liabilities of discontinued operations	$	125	$	4,550